← Back to headlines
FDA Approves Merck's 'Game-Changing' Cholesterol Pill Lipfendra
Merck's new cholesterol therapy, Lipfendra, has received FDA approval in the United States. The once-daily oral PCSK9 inhibitor is described as 'game-changing,' shown to reduce LDL cholesterol by approximately 56% to 60% when combined with statins.
16 Jul, 11:26 — 16 Jul, 13:35
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center
Right1
Right (1)
seeking-alpha
Far R1
Far Right (1)
Fox News
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
Fox NewsMixed17d ago
Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%
Lipfendra, the first once-daily oral PCSK9 inhibitor, was shown to reduce LDL cholesterol by roughly 56% to 60% when combined with statins.
Read full article →seeking-alphaMixed17d ago
Merck cholesterol therapy, Lipfendra, approved in the U.S.
Read full article →Coverage Timeline
First report: seeking-alpha · 16 Jul, 11:26|Full coverage: 2 · 2h|Window: 2h
Left-leaningCenterRight-leaning
